Evidence map›Paper›PMID 35407640›Full record

ArticleJournal of clinical medicine2022

Medium-Term Outcomes in COVID-19.

Zaki Akhtar, Sumeet Sharma, Ahmed I Elbatran, Lisa W M Leung, Christos Kontogiannis, Michael Spartalis, Alice Roberts, Abhay Bajpai, Zia Zuberi, Mark M Gallagher

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zaki AkhtarDepartment of Cardiology, Ashford and St Peter's Hospitals NHS Trust, Surrey KT16 0PZ, UK.
Sumeet SharmaDepartment of Cardiology, Ashford and St Peter's Hospitals NHS Trust, Surrey KT16 0PZ, UK.
Ahmed I ElbatranDepartment of Cardiology, St George's University Hospital, London SW17 0QT, UK.
Lisa W M LeungDepartment of Cardiology, St George's University Hospital, London SW17 0QT, UK.
Christos KontogiannisDepartment of Cardiology, St George's University Hospital, London SW17 0QT, UK.
Michael SpartalisDepartment of Cardiology, National and Kapodistrian University of Athens, 10679 Athens, Greece.ORCID 0000-0002-7442-838X
Alice RobertsDepartment of Cardiology, Ashford and St Peter's Hospitals NHS Trust, Surrey KT16 0PZ, UK.
Abhay BajpaiDepartment of Cardiology, Ashford and St Peter's Hospitals NHS Trust, Surrey KT16 0PZ, UK.
Zia ZuberiDepartment of Cardiology, St George's University Hospital, London SW17 0QT, UK.
Mark M GallagherDepartment of Cardiology, Ashford and St Peter's Hospitals NHS Trust, Surrey KT16 0PZ, UK.ORCID 0000-0002-6333-6420

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 causes severe illness that results in morbidity and mortality. Electrocardiographic features, including QT prolongation, have been associated with poor acute outcomes; data on the medium-term outcomes remain scarce. This study evaluated the 1-year outcomes of patients who survived the acute COVID-19 infection. Methods and Materials: Data of the 159 patients who survived the COVID-19 illness during the first wave (1 March 2020−18 May 2020) were collected. Patient demographics, laboratory findings and electrocardiography data were evaluated. Patients who subsequently died within 1-year of the index illness were compared to those who remained well. Results: Of the 159 patients who had survived the index illness, 28 (17.6%) subsequently perished within 1-year. In comparison to the patients that were alive after 1-year, the deceased were older (68 vs. 83 years, p < 0.01) and equally male (60.4% vs. 53.6%, p = 0.68), with a similar proportion of hypertension (59.5% vs. 57.1%, p = 0.68), diabetes (25.2% vs. 39.2%, p = 0.096) and ischaemic heart disease (11.5% vs. 7.1%, p = 0.54). The QTc interval for the alive and deceased patients shortened by a similar degree from the illness to post-COVID (−26 ± 33.5 vs. −20.6 ± 30.04 milliseconds, p = 0.5); the post-COVID R-R interval was longer in the alive patients compared to the deceased (818.9 ± 169.3 vs. 761.1 ± 61.2 ms, p = 0.02). A multivariate Cox regression analysis revealed that age (HR1.098 [1.045−1.153], p < 0.01), diabetes (HR3.972 [1.47−10.8], p < 0.01) and the post-COVID R-R interval (HR0.993 [0.989−0.996], p < 0.01) were associated with 1-year mortality. Conclusions: The COVID-19-associated mortality risk extends to the post-COVID period. The QTc does recover following the acute illness and is not associated with outcomes; the R-R interval is a predictor of 1-year mortality.

Indexed as

COVID-19mortalityQTcR-R interval

Identifiers

PMID35407640
PMCPMC9000210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.